Milnacipran Film-Coated Tablets Suppliers & Bulk Manufacturers
Available Forms: Film-coated Tablets
Available Strengths: Film-coated Tablets
Reference Brands: Savella(US); Ixel®, Toledomin(EU)
Category:
Antipsychotropic Drugs
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the availability of these neurotransmitters in the central nervous system. It is primarily used to treat fibromyalgia and major depressive disorder (MDD) in some regions. Its balanced dual action helps reduce pain, fatigue, and mood-related symptoms in affected patients.
Milnacipran Film-coated Tablets is available in Film-coated Tablets
and strengths such as Film-coated Tablets.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Milnacipran Film-coated Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Milnacipran Film-coated Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
In the United States, milnacipran film-coated tablets are FDA-approved primarily for the management of fibromyalgia, not for depression, although it's classified as a serotonin-norepinephrine reuptake inhibitor (SNRI). Regulatory requirements include boxed warnings for increased suicidal risk in young adults, GMP compliance, and post-marketing surveillance. Manufacturers must provide evidence of bioavailability, long-term safety, and labeling accuracy.
In the European Union, milnacipran is approved under various national procedures for the treatment of major depressive disorder (MDD), with less emphasis on fibromyalgia. EU regulations mandate a Risk Management Plan (RMP), pharmacovigilance systems, and Periodic Safety Update Reports (PSURs). For dossier-ready supply and partnerships, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing